Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

S-0139 (Shionogi).

J Ruth Wu-Wong¹

¹Abbott Laboratories, Santa Clara, CA 95054, USA. ruth.r.wuwong@abbott.com

Current Opinion in Investigational Drugs (London, England : 2000)

|August 21, 2002

Summary

This summary is machine-generated.

Shionogi and GlaxoSmithKline are developing S-0139, an endothelin-A (ETA) antagonist, for stroke treatment. The drug has undergone phase II trials in Japan and phase I trials in Europe, with a joint venture formed for further development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model.

Journal of exploratory research in pharmacology·2021

Same author

Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.

The Journal of steroid biochemistry and molecular biology·2016

Same author

Preclinical studies of VS-505: a non-absorbable highly effective phosphate binder.

British journal of pharmacology·2016

Same author

Different vitamin D receptor agonists exhibit differential effects on endothelial function and aortic gene expression in 5/6 nephrectomized rats.

The Journal of steroid biochemistry and molecular biology·2014

Same author

Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.

American journal of physiology. Renal physiology·2014

Same author

VS-501: A NOVEL, NON-ABSORBED, CALCIUM- AND ALUMINUM-FREE, HIGHLY EFFECTIVE PHOSPHATE BINDER DERIVED FROM NATURAL PLANT POLYMER.

Pharmacology research & perspectives·2014

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Pharmacology
Neurology
Drug Development

Background:

Shionogi and GlaxoSmithKline (GSK) established a joint venture, Shionogi-GlaxoSmithKline Pharmaceuticals LLC.
This venture focuses on developing S-0139 (SB-737004), an endothelin-A (ETA) antagonist.
S-0139 is being investigated for potential treatment of hemorrhagic and ischemic stroke.

Purpose of the Study:

To develop and commercialize S-0139 for stroke treatment.
To advance S-0139 through clinical trials in Japan, the US, and Europe.

Main Methods:

Phase II clinical trials for stroke were conducted in Japan.
Phase I clinical trials were initiated in Europe.
A joint venture was formed to facilitate global development and commercialization.

Related Experiment Videos

Main Results:

S-0139 progressed to phase II trials in Japan by 1999.
Phase II trials were ongoing as of March 2002.
Phase I trials in Europe were underway by November 2001.

Conclusions:

The joint venture between Shionogi and GSK aims to bring S-0139 to market.
Further development and regulatory submissions are anticipated for S-0139.
The compound shows potential as a therapeutic agent for stroke patients.